Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 3Completed 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 13Recurrence 4Myelodysplastic Syndromes 4Leukemia, Biphenotypic, Acute 4Leukemia, Hairy Cell 3Sarcoma, Myeloid 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Blast Crisis 2Targeted Therapy 1Myeloproliferative Disorders 1Myasthenia Gravis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia 1Burkitt Lymphoma 1

Interventions

Rituximab 4Cladribine 3binimetinib 2Specimen Handling 2CT-P10 2Biopsy 2venetoclax 1tovorafenib 1polatuzumab vedotin 1obinutuzumab 1ibrutinib 1encorafenib 1Vemurafenib 1Spinal Puncture 1Prednisone 1Positron-Emission Tomography 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Hairy Cell × Cladribine × Clear all
NCT06965114 2026-06-03

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT06561360 2026-05-26

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
86 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT00412594 2025-12-22

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
150 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡